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Transcription factors play a key role in tumor development, in which dysfunction of 
genes regulating tissue growth and differentiation is a central phenomenon. The 
GATA family of transcription factors consists of six members that bind to a 
consensus DNA sequence (A/T)GATA(A/G) in gene promoters and enhancers.  The 
two GATA factors expressed in the adrenal cortex are GATA-4 and GATA-6. In both 
mice and humans, GATA-4 can be detected only during the fetal period, whereas 
GATA-6 expression is abundant both throughout development and in the adult. It is 
already established that GATA factors are important in both normal development and 
tumorigenesis of several endocrine organs, and expression of GATA-4 and GATA-6 
is detected in adrenocortical tumors. The aim of this study was to elucidate the 
function of these factors in adrenocortical tumor growth. 
 
In embryonal development, the adrenocortical cells arise and differentiate from a 
common pool with gonadal steroidogenic cells, the urogenital ridge. As the adult 
adrenal cortex undergoes constant renewal, it is hypothesized that undifferentiated 
adrenocortical progenitor cells reside adjacent to the adrenal capsule and give rise to 
daughter cells that differentiate and migrate centripetally. A diverse array of 
hormones controls the differentiation, growth and survival of steroidogenic cells in the 
adrenal gland and the gonads. Factors such as luteinizing hormone and inhibins, 
traditionally associated with gonadal steroidogenic cells, can also influence the 
function of adrenocortical cells in physiological and pathophysiological states. 
 
Certain inbred strains of mice develop subcapsular adrenocortical tumors in 
response to gonadectomy. In this study, we found that these tumors express GATA-
4, normally absent from the adult adrenal cortex, while GATA-6 expression is 
downregulated. Gonadal markers such as luteinizing hormone receptor, anti-
Müllerian hormone and P450c17 are also expressed in the neoplastic cells, and the 
tumors produce gonadal hormones. The tumor cells have lost the expression of 
melanocortin-2 receptor and the CYP enzymes necessary for the synthesis of 
corticosterone and aldosterone. By way of xenograft studies utilizing NU/J nude 
mice, we confirmed that chronic gonadotropin elevation is sufficient to induce 
adrenocortical tumorigenesis in susceptible inbred strains. Collectively, these studies 
suggest that subcapsular adrenocortical progenitor cells can, under certain 
conditions, adopt a gonadal fate.  
 
We studied the molecular mechanisms involved in gene regulation in endocrine cells 
in order to elucidate the role of GATA factors in endocrine tissues. Ovarian granulosa 
cells express both GATA-4 and GATA-6, and the TGF-β signaling pathway is active 
in these cells. Inhibin-α is both a target gene for, and an atypical or antagonistic 
ABSTRACT 
 7 
member of the TGF-β growth factor superfamily. In this study, we show that GATA-4 
is required for TGF-β-mediated inhibin-α promoter activation in granulosa cells, and 
that GATA-4 physically interacts with Smad3, a TGF-β downstream protein. 
 
Apart from the regulation of steroidogenesis and other events in normal tissues, 
TGF-β signaling is implicated in tumors of multiple organs, including the adrenal 
cortex. Another signaling pathway found often to be aberrantly active in 
adrenocortical tumors is the Wnt pathway. As both of these pathways regulate the 
expression of inhibin-α, a transcriptional target for GATA-4 and GATA-6, we wanted 
to investigate whether GATA factors are associated with the components of these 
signaling cascades in human adrenocortical tumors. We found that the expression of 
Wnt co-receptors LRP5 and LRP6, Smad3, GATA-6 and SF-1 was diminished in 
adrenocortical carcinomas with poor outcome. All of these factors drive inhibin-α 
expression, and their expression in adrenocortical tumors correlated with that of 
inhibin-α. The results support a tumor suppressor role previously suggested for 
inhibin-α in the mouse adrenal cortex, and offer putative pathways associated with 
adrenocortical tumor aggressiveness. Unraveling the role of GATA factors and 
associated molecules in human and mouse adrenocortical tumors could ultimately 
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ACA adrenocortical adenoma 
ACC adrenocortical carcinoma 
ACTH  adrenocorticotropic hormone 
AMH  anti-Müllerian hormone 
CREB cAMP response element binding protein 
CRH corticotropin-releasing hormone 
CT computed tomography 
DAX-1 dosage-sensitive sex reversal-adrenal hypoplasia congenita critical 
region on the X chromosome, gene 1 
DBA  dilute brown strain of mice 
DHEA  dehydroepiandrosterone 
DN  dominant negative 
EMSA  electrophoretic mobility shift assay 
FOG  friend of GATA 
GnRH  gonadotropin-releasing hormone 
hCG  human chorionic gonadotropin 
HU  Hounsfield unit 
LH  luteinizing hormone 
LHR  luteinizing hormone receptor 
LRP  low density lipoprotein receptor-related protein 
MAP  mitogen-activated protein 
MC2R  melanocortin-2 receptor 
MEN1  multiple endocrine neoplasia, type 1 
P450c17 cytochrome P450 17α-hydroxylase/17,20-lyase 
PCOS  polycystic ovary syndrome 
PKA  protein kinase A 
PPNAD primary pigmented nodular adrenocortical disease 
RT  reverse transcriptase 
SF-1  steroidogenic factor-1 
sFRP1 secreted frizzled-related protein-1 
StAR  steroidogenic acute regulatory protein 
SULT2A1 dehydroepiandrosteronesulfotransferase 
TGF  transforming growth factor 
Wnt  wingless-related mouse mammary tumor virus integration site 
wt  wild type 
WT-1  Wilm’s tumor-1 
zF  zona fasciculata 
zG  zona glomerulosa 





The adrenal gland is a major steroid-secreting organ and part of the hypothalamic-
pituitary-adrenal axis. In mammalian embryogenesis, the cells destined to form the 
adrenal cortex arise from a pool of mesodermal progenitors, termed the urogenital 
ridge, that also gives rise to the steroidogenic cells of the gonads. The adrenocortical 
progenitors then associate with neural crest derivatives that will give rise to the 
adrenal medulla. 
 
Transcription factors are proteins that regulate gene expression in cells by binding to 
specific DNA sequences – promoters and enhancers of the genes. In mammalian 
development, differentiation and growth of the organs is regulated by a complex set 
of genes. Transcription factors also play a key role in tumor development, in which 
dysfunction of genes regulating tissue growth and differentiation is one of the central 
phenomena. This study focuses on one group of transcription factors, the GATA 
factors, and on their significance in tumors of the adrenal cortex. 
 
Of the six GATA factors, GATA-4 and GATA-6 are expressed in the mouse and 
human adrenal cortex. GATA-4 expression is confined to the fetal cortex, while 
GATA-6 is expressed in both fetal and adult adrenal glands. In vitro, GATA-4 
regulates inhibin-α and steroidogenic factor-1, which are important for normal adrenal 
function. GATA-6 probably has roles in the regulation of steroidogenesis and in the 
development and differentiation of adrenocortical cells. Disruption of either the Gata4 
or Gata6 gene in mice results in early embryo lethality which, while underscoring 
their importance in embryonal development, has hampered investigations of these 
factors in the adrenal cortex and other endocrine tissues. 
 
GATA factors have already been found to be important in both normal development 
and tumor growth of several endocrine organs. In granulosa cell tumors and 
adrenocortical carcinoma, high GATA-4 expression has been associated with 
aggressive behavior. We investigated the function of these factors and their cofactors 
in granulosa cell signaling and in tumors of the human and mouse adrenal cortex, to 
elucidate their role in the molecular mechanisms of tumor growth. 
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Review of the Literature 
 
1 Development and function of the adrenal gland 
 
1.1 Fetal period 
 
In embryonal development, the adrenal cortexes are formed from mesoderm-derived 
cells in the urogenital ridge. The cells of the adrenal medulla migrate from the 
ectodermal neural crest. In addition to the adrenal cortexes, the urogenital ridge 
gives rise to kidneys and the stromal cells of the gonads. As a result of this common 
embryonal origin, adult gonads may sometimes contain patches of adrenocortical 
cells, and in turn, adrenocortical cells are in some circumstances able to adopt 
gonadal characteristics. 
 
By embryonal day 9.5 in mice, a subset of urogenital cells termed the adrenogonadal 
primordium can be distinguished by expression of the transcription factor 
steroidogenic factor-1 (SF-1) (Hanley, et al. 1999; Ikeda, et al. 1994). A separate 
adrenocortical primordium is distinguishable by embryonal day 11.5 (Hatano, et al. 
1996). In addition to SF-1, other early regulators of adrenogonadal development are 
Wilm’s tumor-1 (WT1), wingless-related mouse mammary tumor virus integration site 
4 (Wnt4) and dosage-sensitive sex reversal-adrenal hypoplasia congenita critical 
region on the X chromosome, gene 1 (DAX-1), also expressed in adrenogonadal 
primordium. Each of these factors is critical to proper differentiation of adrenocortical 
and gonadal stromal cells (Bardoni, et al. 1994; Keegan and Hammer 2002; 
Kreidberg, et al. 1993; Luo, et al. 1994; Vainio, et al. 1999; Yu, et al. 1998) (figure 1). 
 
Early development of the adrenal gland is very similar in humans and mice. By the 
4th week of human gestation, the adrenogonadal primordium is evident, and by 8th 
week of gestation the caudal cells destined to form the adrenal gland have migrated 
to the cranial end of the mesonephros, forming the adrenocortical primordium 
(Mesiano and Jaffe 1997). At this stage, the primordium comprises an inner fetal 
zone and a thin, outer definitive zone. Shortly thereafter the medullary cells migrate 
from the neural crest into the primordium and the adrenal becomes encapsulated 
(Mesiano and Jaffe 1997). 
 
 






Development of the urogenital ridge derivatives and a simplified model of developmental 
regulation as studied in genetically engineered mice. Mutations in the key regulatory genes 
WT1, SF1 and Wnt4, expressed in the urogenital ridge or adrenogonadal primordium, disrupt 
both adrenal and gonadal development (Keegan and Hammer 2002; Kreidberg et al. 1993; 
Luo et al. 1994; Vainio et al. 1999). Mutations in melanocortin-2 receptor (MC2R, 
adrenocorticotropic hormone receptor) or luteinizing hormone receptor (LHR), expressed in 
cells differentiated to adrenal or gonadal directions, respectively, have effects mostly on 
postnatal development (Chida, et al. 2007; Lei, et al. 2001; Zhang, et al. 2001). 
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1.2 Postnatal period 
 
After birth, the adrenal cortex undergoes marked changes. In humans, the fetal zone 
regresses and the definitive zone expands, forming the zona glomerulosa (zG) and 
the zona fasciculata (zF) (Mesiano and Jaffe 1997). The adult zonal pattern is 
established during 10–20 years of age (Sucheston and Cannon 1968); the adult 
adrenal cortex consists of the outermost zG, the middle zF and the inner zona 
reticularis (zR). In mouse adrenal cortex, in contrast, zonation is already complete by 
birth. In addition to the zG and the zF, the postnatal adrenal cortex consists of a layer 
termed the X-zone, which is derived from the recently recognized mouse fetal zone 
(Zubair, et al. 2006). The X-zone, which has been suggested to participate in 
progesterone catabolism (Hershkovitz, et al. 2007), regresses during puberty in 
males and during the first pregnancy in females. In the mouse adrenal cortex, no zR 
is seen, and consequently its function also differs from that of humans (table 1). 
 
  Human Mouse 
Zona glomerulosa Zona glomerulosa 
Zona fasciculata Zona fasciculata 
Zona reticularis X-zone / fetal zone 
Morphologically distinct zones 
Fetal zone  
P450c17 ++ - 
Major glucocorticoid produced Cortisol Corticosterone 
Production of androgenic 
steroids ++ - 
Table 1. Comparative anatomy and physiology of human and mouse adrenal cortex. 
Modified from (Bielinska, et al. 2006). Abbreviation: P450c17, cytochrome P450 17α-
hydroxylase/17,20-lyase 
 
The adult adrenal cortex undergoes constant renewal. The adrenocortical cells are 
believed to be derived from subcapsular stem/progenitor cells and to migrate 
centripetally, in turn adopting characteristics specific for each zone (Kim and 
Hammer 2007; Schulte, et al. 2007). The human adrenal cortex secretes various 
steroid hormones (figure 2), mainly aldosterone (zG), cortisol (zF), and 
dehydroepiandrosterone (DHEA) and other androgens (zR). The most prominent 
difference between mouse adrenal steroid production, in contrast to humans and 
most other rodents, is the lack of cytochrome P450 17α-hydroxylase/17,20-lyase 
(P450c17) in the adult mouse adrenal cortex (Keeney, et al. 1995). Thus, no 
REVIEW OF THE LITERATURE 
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androgens are produced in the mouse adrenal, and the main glucocorticoid is 







Steroid hormone biosynthetic pathways. The steroidogenic capacity in a given cell depends 
on the enzymes available. Abbreviations: P450scc, P450 side-chain cleavage; 3β-HSD, 3β-
hydroxysteroid dehydrogenase; 17β-HSD, 17β-hydroxysteroid dehydrogenase; DOC, 
deoxycorticosterone; DHEA, dehydroepiandrosterone; DHEA-S, dehydroepiandrosterone 
sulfate; P450aldo, aldosterone synthase; P45019a1, aromatase; P450c11, cytochrome P450 
11β-hydroxylase; P450c17, cytochrome P450 17α-hydroxylase/17,20-lyase; P450c21, 
cytochrome P450 21-hydroxylase. 
 
The adrenal cortex functions as part of the hypothalamic-pituitary-adrenal axis (see 
figure 5 in 2.3.2). The hypothalamus secretes corticotropin-releasing hormone 
(CRH), which promotes the secretion of adrenocorticotropic hormone (ACTH), the 
pituitary tropic hormone responsible for the secretion of cortisol and androgens from 
the adrenal cortex (Mesiano and Jaffe 1997). The adrenocortical corticosteroids in 
turn inhibit excess CRH production from the hypothalamus, creating a negative 
feedback loop. The regulation of aldosterone secretion is not dependent on ACTH. 
The chromaffin cells of the adrenal medulla, derived from neural crest cells, are the 
source of the stress hormones adrenaline and noradrenaline. 
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2 GATA family of transcription factors 
 
Transcription factors are regulator proteins critical for cellular diversity. They bind to 
specific sites on the promoter region of a gene, thus regulating gene expression in a 
given cell. The GATA family of zinc finger transcription factors is named after a 
(A/T)GATA(A/G) binding site on a gene’s promoter (Tremblay and Viger 2003a). The 
family consists of six members, GATA-1 through GATA-6 (table 2). GATA-1, GATA-2 
and GATA-3 are primarily associated with hematopoiesis, while GATA-4, GATA-5 
and GATA-6 are expressed in various endocrine and other mesoderm-derived 
tissues. Null mutations of Gata genes, except for Gata5, are embryonic lethal, 




The structure of the GATA factors is based on two zinc fingers binding DNA and 
cofactors. Situated next to the C-terminal zinc finger is a nuclear localization signal, 
which together with the zinc fingers constitutes the DNA binding and protein-protein 
interaction domain, and additional transcriptional activation domains are located N-
terminally (Molkentin 2000; Morrisey, et al. 1997). The C-terminal zinc finger and the 
adjacent nuclear localization signal are conserved through species (Lowry and 
Atchley 2000). In addition, among the GATA family members, the zinc fingers share 
considerable homology (figure 3), which could be expected to lead to functional 
redundancy. However, in vivo the roles of the GATA factors often seem to be 
relatively distinct and non-redundant, and the presence of many other factors 
controlling tissue-specific transcription is documented in many tissues (Viger, et al. 
2008). 







Structure and homology of the GATA proteins. The light gray area represents the zinc finger 
(ZnF) domain and the dark gray area represents the nuclear localization sequence. This 
region binds DNA and is involved in protein interactions with cofactors and other 
transcriptional partners.  The percentage homology in the zinc finger domain is indicated. 
Abbreviations: ZnF, zinc finger; N, N-terminus; C, C-terminus. Modified from (Viger et al. 
2008). 
 
2.2 Tissue-specific expression and knockout phenotypes 
 
GATA factors are expressed in a wide variety of tissues (table 2). Null mutations of 
the Gata genes, excluding Gata5, each arrest development at an early stage, which 
has been a challenge for research into the function of GATA factors in adult tissues. 
 
GATA factors can be divided in two subgroups based on their expression pattern, the 
hematopoietic group and the cardiac group (figure 3 and table 2). GATA-1, GATA-2 
and GATA-3 are primarily expressed in hematopoietic cells and are essential to the 
differentiation and proliferation of the hematopoietic lineage (Weiss and Orkin 1995). 
GATA-4, GATA-5 and GATA-6 are, in contrast, expressed in a variety of mesoderm- 
and endoderm-derived tissues, including the heart, gut, gonads and adrenal gland 
(Molkentin 2000). In particular, the role of GATA-4 and GATA-6 in the heart has been 
extensively studied (Pikkarainen, et al. 2004). Mice lacking GATA-4 or GATA-6 die in 
utero by E10.5 as a result of severe defects in development; Gata4 null mice have 
defects in ventral morphogenesis and heart tube formation, while in Gata6 null mice, 
endoderm differentiation is blocked (Kuo, et al. 1997; Molkentin, et al. 1997; 
Morrisey, et al. 1998). The Gata5 null mutation is the only one of the GATA factor 
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mutations resulting in a viable mouse (Molkentin, et al. 2000). However, a recent 
report suggests functional redundancy for GATA-4 and GATA-5 in the heart, as 
double mutant mice, Gata5 null and heterozygous for Gata4, die in utero as a result 
of cardiovascular defects (Singh, et al. 2010). 
 
The friend of GATA (FOG) proteins FOG-1 and FOG-2 are specific co-regulators of 
GATA factors. They contain zinc fingers by which they bind and interact with GATA 
factors, either by enhancing or antagonizing (Cantor and Orkin 2005). Null mutation 
of Fog1 results in a failure in hematopoiesis, and mice null for Fog2 have severe 
cardiac defects; both knockout phenotypes are embryonic lethal (Svensson, et al. 
2000b; Tevosian, et al. 2000; Tsang, et al. 1998). FOG-1 is expressed in 
hematopoietic cells, as expected from the null mutation phenotype, and also in other 
tissues such as testis and gut (Cantor and Orkin 2005; Jacobsen, et al. 2005). FOG-
2 is expressed in the heart, where it interacts with GATA-4: if the N-terminal zinc 
finger of GATA-4 is mutated to prohibit the interaction, a mouse phenotype similar to 
the Fog2 null mouse develops (Crispino et al., 2001). This underlines the importance 
of GATA:FOG interactions. FOG-2 is also expressed in the gonads (Viger et al. 
2008), and in addition to heart defects, gonadal dysgenesis has been detected in a 
human mutation of the Fog2 gene (Finelli, et al. 2007). 




  tissue expression 
mouse null mutation 
phenotype human mutation 
GATA-1 Hematopoietic lineage, testis 
Lethal (E11.5), failure in 
hematopoiesis 
(Fujiwara, et al. 1996) 
Anemia, 
thrombocytopenia (loss-
of-function mutation of 
the FOG-1 binding site) 
(Nichols, et al. 2000) 
GATA-2 Hematopoietic lineage 
Lethal (E11.5), failure in 
hematopoiesis (Tsai, et 
al. 1994) 
Acute phase of chronic 
myeloid leukemia (gain-
of-function mutation) 
(Zhang, et al. 2008) 
GATA-3 T-cells, central nervous system 
Lethal (E11.5), failure in 
hematopoiesis and 
CNS defects (Pandolfi, 
et al. 1995) 
HDR syndrome (loss-of-
function mutation) (Van 
Esch, et al. 2000) 
GATA-4 Adrenal gland, gonads, heart 
Lethal (E10.5), defects 
in heart formation (Kuo 












(Molkentin et al. 2000) 
Not detected 
GATA-6 Adrenal gland, gonads, heart 
Lethal (E7.5), failure in 
gastrulation (Morrisey et 
al. 1998) 
Not detected 
FOG-1 Hematopoietic lineage, testis 
Lethal (E11.5), failure in 
hematopoiesis (Tsang 
et al. 1998) 
Not detected (see 
GATA-1) 
FOG-2 Gonads, heart, brain 
Lethal (E12.5), defects 
in heart development 
(Svensson et al. 2000b; 
Tevosian et al. 2000) 
Congenital heart 
defects and gonadal 
dysgenesis (loss-of-
function mutation) 
(Finelli et al. 2007) 
Table 2. GATA and FOG factor expression, knockout phenotypes and mutations 
detected in humans. Abbreviations: FOG, friend of GATA; CNS, central nervous 
system; HDR, hypoparathyroidism-deafness-renal dysplasia 
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2.3 GATA factors in the derivatives of adrenogonadal primordium 
 
Within the Gata family, GATA-4 and GATA-6 are specifically involved in development 
and differentiation of the steroidogenic tissues of the adrenals and gonads. The 
adrenal cortex in both humans and mice expresses GATA-4 and GATA-6. GATA-6 is 
abundantly expressed throughout development and adulthood (Kiiveri, et al. 2002; 
Nemer and Nemer 2003). During human fetal development, GATA-6 expression is 
seen both in the fetal and definitive zones. In adults, GATA-6 is expressed in the zR 
and the zF. In mice, GATA-6 is also expressed both in the fetal and adult adrenal 
cortex. GATA-4, in contrast, is expressed only in fetal adrenals, both in humans and 
mice (Kiiveri et al. 2002). The Gata4 expression pattern in the fetal mouse adrenal 
resembles that of P450c17 (Keeney et al. 1995), and although there is no direct 
proof, it can be speculated that GATA-4 enhances expression of P450c17 in the fetal 
adrenal. 
 
GATA-4 does not seem to be essential for early adrenocortical development, as 
studied in mice chimeric for Gata4-/- and wild-type cells (Kiiveri et al. 2002; Tevosian, 
et al. 2002), but it is a cofactor for the developmentally critical protein SF-1 (Tremblay 
and Viger 1999). In vitro, it also upregulates the expression of several proteins 
involved in the function of the adrenal gland, such as inhibin-α, P450c17, and 
steroidogenic acute regulatory protein (StAR) (Tremblay and Viger 2003a). GATA-6 
also regulates several steroidogenic enzymes in transactivation experiments. By 
acting in synergy with SF-1, it upregulates the expression of P450c17, P450scc, 
StAR and dehydroepiandrosteronesulfotransferase (SULT2A1), which are proteins 
necessary for adrenal steroid biosynthesis (Jimenez, et al. 2003; Tremblay and Viger 
2003a). 
 
Although the gonads share the same developmental origin with the adrenals, the 
GATA factor expression profile is different. As early as in the urogenital ridge, GATA-
4 is expressed in the cells destined to form gonadal somatic cells, and the expression 
persists throughout development. In adults, GATA-4 is present in several gonadal 
cell lineages, including male Leydig cells and female granulosa and theca cells (Viger 
et al. 2008). GATA-6 is also expressed in gonadal somatic tissue during development 
and adulthood (Heikinheimo, et al. 1994; Ketola, et al. 1999). Several of the GATA 
target genes are shared between the adrenals and gonads, including SF-1, StAR and 
inhibin-α. Specifically gonadal regulators are the GATA-4 target genes anti-Müllerian 
hormone and aromatase. GATA-6 has also been proposed to transactivate several of 
these regulators of gonadal development and function (Tremblay and Viger 2003a). 
 
GATA-6 protein expression has been found to be significantly diminished in most 
human adrenocortical adenomas and carcinomas. However, supporting its proposed 
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role in adrenal androgen biosynthesis in the zR, its expression is retained in a 
fraction of virilizing tumors, especially carcinomas (Bassett, et al. 2005; Kiiveri, et al. 
2005; Kiiveri, et al. 1999). GATA-4 mRNA is, in contrast, expressed only in a small 
proportion of human adrenocortical tumors, and it seems to be associated with 
aggressive behavior (Barbosa, et al. 2004; Bassett et al. 2005; Kiiveri et al. 2005; 
Kiiveri et al. 1999). 
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3 Adrenocortical tumors 
 
3.1 Human adrenocortical tumors 
 
Incidentalomas are adrenal masses found by incident when a radiologic examination, 
e.g. computed tomography (CT) of the abdomen, is performed for an indication other 
than evaluation of the adrenals. As ultrasonography, CT and magnetic resonance 
imaging are increasingly being utilized in medical diagnostics, the occurrence of 
incidentalomas has increased: the probability of finding an adrenal mass in an 
abdominal CT examination is now about 7% in a patient over 70 years of age (Kloos, 
et al. 1995; Young 2007) . 
 
The majority of incidentalomas are benign adrenocortical adenomas. The true 
incidence is unknown, but according to autopsy studies, adrenocortical adenomas 
affect approximately 5% of the population (Brunt and Moley 2001). Most often they 
do not require treatment, being clinically nonhypersecreting and asymptomatic. If, 
however, the tumor is functional, i.e. hormone-secreting, or if its radiological features 
are suspicious as regards malignancy, it is surgically removed (Bertherat, et al. 
2002). The CT imaging features that associate with adenomas are small size (< 3 cm 
diameter), sharp margins and low density (< 10 Hounsfield units (HU)) (Brant and 
Helms 2006). Approximately 30% of adenomas have a low fat content, resulting in a 
density of 10–30 HU. The washout of intravenously administered contrast material is 
measured in these cases; benign lesions typically demonstrate more than 50% 
washout (Brant and Helms 2006). 
 
The hormones secreted by adrenocortical adenomas are usually the same as those 
that are produced by the normally functioning cortex. Hormonally active tumors are 
divided according to the major hormone secreted: Cushing’s (glucocorticoids) which 
are the most common, Conn’s (aldosterone), and the rare virilizing (androgens) or 
feminizing (estrogen) adenomas (Bertherat et al. 2002; DeLellis, et al. 2004). Most of 
the androgen- and estrogen-secreting adrenocortical tumors are carcinomas. 
 
Other than an adrenocortical adenoma, an incidentaloma can be a 
pheochromocytoma originating from adrenal medullary cells, a metastasis, or primary 
adrenocortical carcinoma, among other things. Adrenocortical carcinoma is a rare 
disease, with an incidence of approximately 1 case per million people per year, but 
its prognosis is poor and it often presents with metastases (Barlaskar and Hammer 
2007; Volante, et al. 2008). About 80% of these carcinomas are functional, most 
commonly secreting glucocorticoids (45%), glucocorticoids plus androgens (45%), or 
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androgens (10%). Primarily aldosterone-secreting adrenocortical carcinomas are 
very rare, representing less than 1% of all the cases. 
 
The histopathological grading of adrenocortical tumors is often carried out according 
to the criteria of Weiss (DeLellis et al. 2004; Weiss 1984; Weiss, et al. 1989) (table 
3). Of the 9 criteria, the presence of three or more highly correlates with subsequent 
malignant behavior. Generally, scores 0–2 are considered clearly benign and 4–9 
clearly malignant; score 3 has been called the “grey zone” (Tissier 2010), as although 
originally considered malignant by Weiss (Weiss et al. 1989), there have been 
several reports of score-3 tumors that did not recur (Tissier 2010). On the other hand, 
that is not proof that these tumors were indeed benign. Weiss score-3 tumors could 
be described as having malignant potential. Other systems for distinguishing 
between benign and malignant adrenocortical tumors have also been developed, 
including nonhistologic criteria such as tumor mass and clinical features (Hough, et 
al. 1979; van Slooten, et al. 1985). A modification of the Weiss system, adding more 
weight to the mitotic rate and the cytoplasmic characteristics, has been proposed 
(Aubert, et al. 2002), and some investigators believe that the criteria for malignancy 
differ for pediatric tumors (Ribeiro, et al. 1990). 
 
 
1. High nuclear grade; Fuhrman criteria 
2. >5 mitoses per 50 high-power fields 
3. Atypical mitotic figures 
4. <25% of tumor cells are clear cells 
5. Diffuse architecture (>33% of tumor) 
6. Necrosis 
7. Venous invasion 
8. Sinusoidal invasion 
9. Capsular invasion 
Table 3. Histopathologic criteria proposed by Weiss (Weiss 
1984; Weiss et al. 1989) for distinguishing benign from 
malignant adrenocortical neoplasms. The presence of three 
or more criteria highly correlates with subsequent malignant 
behavior. 
 
It has been reported that postmenopausal women (Fidler 1977), and men with 
acquired testicular atrophy (Romberger and Wong 1989) develop subcapsular 
adrenocortical neoplasms that histologically resemble ovarian tissue. It has been 
REVIEW OF THE LITERATURE 
 23 
speculated that elevated luteinizing hormone (LH) levels or decreased sex steroid 
levels might account for the development of these tumors (Bielinska et al. 2006). 
Interestingly, a similar phenomenon has been observed in mice and will be discussed 
in the next chapter. 
 
3.2 Mouse models 
 
The close developmental relationship between the adrenal gland and the gonads can 
become manifest in pathological conditions. In certain instances, factors traditionally 
associated with gonadal steroidogenesis may influence the differentiation, 
proliferation and function of adrenocortical progenitor cells. 
 
As early as in the 1940s it was observed that after gonadectomy, mice develop 
subcapsular neoplasia in their adrenals (Fekete, et al. 1941). However, this 
phenomenon is evident only in certain inbred mouse strains, such as DBA/2J, C3H 
and CE/J, of which the latter develops carcinomas, while other strains such as 
C57BL/6J and FVB/N are resistant to gonadectomy-induced neoplasia (Bielinska, et 
al. 2009). The susceptibility was later linked to a polymorphism in the SF-1 gene 
(Frigeri, et al. 2002). Additionally, linkage analysis of crosses between a susceptible 
and a non-susceptible strain (DBA/2J and C57BL/6J) showed that tumorigenesis 
following gonadectomy is a dominant trait and that a major locus for tumorigenesis is 
on chromosome 8 (Bernichtein, et al. 2008). One of the candidate genes in this 
region is proposed to be that for secreted frizzled-related protein-1 (sFRP1), which is 
a tumor suppressor inhibiting the Wnt/β-catenin signaling pathway (Bernichtein et al. 
2008). 
 
The adrenocortical neoplasms that develop in susceptible strains arise subcapsularly 
and invade the deeper layers of the cortex, displacing normal adrenocortical tissue. 
Two different populations of cells make up the neoplasms: small, basophilic cells 
termed A cells and large, lipid-laden cells termed B cells (Fekete et al. 1941; 
Woolley, et al. 1952) (figure 4).  
 





H&E staining of a neoplastic adrenocortical 
region in gonadectomized DBA/2J mice. A: 2 
months after gonadectomy A cells 
accumulate subcapsularly and extend 
between the epithelial cell columns (arrow). 
B: 6 months after gonadectomy B cells (large 
arrow) have developed in between the A cells 
(small arrow). Bar, 50 µm. Modified from 
(Bielinska, et al. 2003). 
 
Genetically modified mouse models of adrenocortical tumors have also been 
developed. Mice lacking the inhibin-α gene (Inha -/-) develop gonadal tumors but, 
when gonadectomized, adrenocortical tumors with gonadal characteristics arise 
(Matzuk, et al. 1994; Matzuk, et al. 1992). Transgenic mice expressing simian virus 
T-antigen driven by the inhibin-α promoter (Inhα/Tag) similarly initially develop 
gonadal tumors and, post-gonadectomy, adrenocortical tumors (Kananen, et al. 
1996; Kananen, et al. 1995). In the adrenals of gonadectomized Inhα/Tag mice, type 
A- and type B-like cells can be observed near the adrenal capsule (Rahman, et al. 
2004), although the actual tumors are situated at a juxtamedullar position in the X 
zone. It has been proposed that the origin of these tumors could also be the 
subcapsular progenitor cells (Looyenga and Hammer 2006). 
 
Chronic elevation of circulating gonadotropin concentrations is a prerequisite for 
tumor formation in all of these mouse models, as studied by either surgical, 
pharmacological or mutational abrogation of the gonadotropin effects (Huseby and 
Bittner 1951; Kumar, et al. 1995; Rahman, et al. 1998; Rilianawati, et al. 1998). LH is 
a dimeric glycoprotein hormone, secreted in a pulsatile manner from the pituitary in 
response to a surge of gonadotropin-releasing hormone (GnRH). LH receptors 
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(LHRs), present on gonadal steroidogenic cells and, at a very low level, in normal 
human adrenal cortex (Couzinet, et al. 2001; Pabon, et al. 1996), bind the LH protein 
on the cell surface. Via several signaling pathways, including the cAMP/protein 
kinase A (PKA) pathway, the mitogen-activated protein (MAP) kinase pathway and 
the phosphatidylinositol-3-kinase pathway, LHRs transmit effects on cell growth, 
differentiation and steroid production by activation of transcription factors inducing 
expression of steroidogenic enzyme genes (Huhtaniemi, et al. 2002; Tremblay and 
Viger 2003a). Under normal conditions, the sex steroids secreted signal back to the 
hypothalamus, inhibiting GnRH production; a similar negative feedback loop as in the 
hypothalamic-pituitary-adrenal axis. After gonadectomy, however, the negative 
feedback is absent, allowing continuously elevated levels of LH and other 
gonadotropins. Figure 5 summarizes the hypothalamic-pituitary-adrenal/gonadal 






The hypothalamic-pituitary-adrenal/gonadal axis in intact (left) and gonadectomized (right) 
mice. In intact mice, the steroids produced by the adrenals and gonads send negative 
feedback to the hypothalamus and the pituitary, while in gonadectomized mice the negative 
feedback from the gonads is absent. Abbreviations: CRH, corticotropin-releasing hormone; 
GnRH, gonadotropin-releasing hormone; ACTH, adrenocorticotropic hormone; LH, luteinizing 
hormone. Modified from (Bielinska et al. 2006). 
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4 Molecular pathophysiology of adrenocortical tumorigenesis 
 
Signaling pathways involved in normal embryonal development are often aberrantly 
active in neoplastic processes. Adrenocortical tumors are no exception, as many of 
the growth and differentiation factors important for adrenal development are 
implicated in tumors of the adrenal cortex. 
 
4.1 Subcapsular stem/progenitor cells 
 
The adrenal cortex constantly renews itself by turnover of the steroidogenic cells. It is 
theorized that multipotential stem/progenitor cells reside in the subcapsular region of 
the cortex and give rise to daughter cells that differentiate, migrate centripetally, and 
in turn adopt the characteristics of each functional zone (Bielinska et al. 2006; Kim 
and Hammer 2007; Schulte et al. 2007). The molecular characteristics of the 
progenitor cells that are derived from the quiescent subcapsular stem cells include 
expression of SF-1 and DAX-1 (figure 6). DAX-1 acts as a repressor of steroidogenic 
gene expression, which limits the steroidogenic capacity of the subcapsular 
progenitors. In response to ACTH, Dax1 is downregulated and the cells differentiate 
into corticoid-producing cells that express GATA-6. The binding of ACTH to its G-
protein-coupled receptor, melanocortin-2 receptor (MC2R), drives differentiation of 
adrenocortical progenitors into corticoid-producing cells. It is hypothesized that the 
subcapsular stem/progenitor cells are principal targets of neoplastic transformation in 
the adrenal cortex (Bielinska et al. 2006; Doghman, et al. 2007; Kim and Hammer 
2007).  
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Figure 6. 
Differentiation of multipotential 
subcapsular adrenocortical 
progenitor cells into corticoid-
producing cells. Dax-1 is 
downregulated in response to 
ACTH, and the cells differentiate 
into MC2R- and GATA-6-




4.2 Wnt/β-catenin signaling 
 
The Wnt signaling pathway regulates many developmental processes, such as cell-
fate determination, cell proliferation and adhesion (Prunier, et al. 2004). Molecules of 
the Wnt family bind to cell surface frizzled receptors, which bind the low density 
lipoprotein receptor-related protein (LRP) co-receptors and initiate a signaling 
cascade. The canonical Wnt signal is transmitted via the cytoplasmic mediator β-
catenin, which is translocated to the nucleus and can there enhance transcription of a 
specific gene, together with cofactors such as SF-1 on inhibin-α activation in 
steroidogenic cells (Gummow, et al. 2003). Wnts can also act through non-canonical, 
β-catenin independent pathways, the jun N-terminal kinase pathway and the calcium 
pathway (Rao and Kuhl 2010). In the mouse adrenal cortex, Wnt4 is expressed in the 
zG and, as shown in knockout studies, contributes to its function (Heikkila, et al. 
2002). Wnt4 null mice have decreased expression of P450aldo in the adrenal cortex 
and in contrast, ectopic expression of adrenocortical P450c21 in gonadal tissue 
(Heikkila et al. 2002; Jeays-Ward, et al. 2004). Wnt4 may thus play a role in cell 
migration or in the sorting of adrenocortical and gonadal cells in early development. 
Another member of the Wnt family expressed in the adrenal cortex is Wnt2b, which is 
found in the subcapsular progenitor cells (Lin, et al. 2001). 
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4.3 TGF-β/Smad signaling 
 
Transforming growth factor beta (TGF-β) signaling is mediated through a receptor 
complex comprising type I and type II serine/threonine kinase receptors. The ligand 
binds to the type II receptor, which activates the complex and transmits the signal by 
phosphorylating the intracellular Smad proteins. These ubiquitous proteins then 
become translocated to the nucleus and interact with cell-specific transcription 
factors and other regulators to drive expression of target genes (Shi and Massague 
2003) (figure 7). The cell-specific cofactors are essential for the functional diversity of 
TGF-β signaling, as only two types of Smad responses are known: the bone 
morphogenic protein subfamily activates Smad1, Smad5 and Smad8, whereas the 
TGF-β subfamily activates Smad2 and Smad3. Other Smad proteins participating in 
signal transmission are Smad4, a coactivator, and co-inhibitors Smad6 and Smad7. 
 
Activin and inhibin are dimeric glycoproteins that belong to the TGF-β superfamily. 
They function as endocrine, paracrine and autocrine regulators of pituitary and 
gonadal function, and also influence the adrenal gland (Beuschlein, et al. 2004; 
Drummond, et al. 2004; Risbridger, et al. 2001). The inhibin-activin system involves 
three genes, Inha, Inhba and Inhbb, that respectively encode monomeric protein 
subunits α, βA and  βB. These subunits form homo- and heterodimers: inhibins, in 
which the α-subunit is present (inhibin A and inhibin B), and activins, which are 
formed by the β-subunits alone (activin A, activin B, or activin AB). 
 
There is no known specific receptor for inhibins, so they are considered to 
antagonize activin by preventing its binding to the TGF-β receptor (Stenvers and 
Findlay 2010). Activin receptors are expressed in mouse adrenal gland, and activins 
have been shown to inhibit adrenocortical cell growth and enhance apoptosis in the X 
zone in mice (Beuschlein, et al. 2003). Although the phenotype of Inha -/- mice 
suggests that the α subunit of inhibin is a tumor suppressor, the absence of inhibin-α 
is not required for tumor formation. In contrast, strong inhibin-α expression has been 
detected in at least ferret and human adrenocortical tumors (Arola, et al. 2000; 
Peterson, et al. 2004; Vanttinen, et al. 2003).  
4.4 cAMP signaling 
 
Activation of G-protein-coupled receptors on the surface of endocrine cells has 
various effects on cell growth, differentiation and steroid production. The ACTH 
receptor MC2R and the LH receptor are examples of G-protein-coupled receptors, 
mediating their signals in part through the well characterized cAMP/PKA pathway. 
The cAMP response element binding protein (CREB) translocates to the nucleus to 
enhance the expression of steroidogenic enzyme genes. Because many of the 
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cAMP-responsive endocrine genes lack cAMP response element (CRE) sites, the 
response requires other (cell-specific) transcription factors such as GATA-4, GATA-6 
and SF-1 (Parker and Schimmer 1997; Tremblay and Viger 2003a). Dysregulation of 






A simplified schematic illustration of the canonical Wnt/β-catenin signaling pathway, the 
TGF-β/Smad pathway and the cAMP/PKA pathway from the cell surface to the nucleus. 
Signals are transmitted via intracellular mediators to the nucleus, where the mediator 
proteins bind to gene promoter regions together with cell-specific transcription factors. As a 
result, transcription of a given gene, such as inhibin-α, is enhanced or inhibited. See text for 
details. 
 
4.5 Molecular mechanisms in human adrenocortical tumors 
 
The pathogenesis of adrenocortical tumors in humans remains mostly unresolved. 
Certain genetic conditions predispose individuals to adrenocortical tumors (table 4), 
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and although each of them is rare, they have given valuable insight into the 
mechanisms of adrenocortical neoplastic growth. 
 
Carney complex is a multiple neoplasia syndrome featuring a variety of 
mucocutaneous pigmented lesions and cardiac, cutaneous, neural and endocrine 
tumors (Carney, et al. 1986). A mutation in the PRKAR1A gene causes increased 
PKA activity by affecting its regulatory subunit (Kirschner, et al. 2000), and its 
adrenocortical manifestation is primary pigmented nodular adrenocortical disease 
(PPNAD). Another syndrome in which the cAMP/PKA pathway is dysregulated is 
McCune-Albright syndrome. It is a pediatric sporadic syndrome defined by the triad of 
polyostotic fibrous dysplasia, café-au-lait skin lesions and sexual precocity. Patients 
may develop nodular hyperplasia or adenomas of the adrenal cortex, and 
hypersecretion of hormones may also occur. McCune-Albright syndrome is caused 
by activating mutations on Gsα, a heterotrimeric G protein α-subunit (Lumbroso, et 
al. 2002). Li-Fraumeni syndrome is caused by an inactivating germline mutation in 
tumor suppressor TP53 and it leads to familial susceptibility to cancer (Malkin 1993; 
Malkin, et al. 1990). Affected individuals may also develop adrenocortical carcinoma, 
although rarely. Multiple endocrine neoplasia, type 1 (MEN1) is an autosomal 
dominant syndrome in which the MEN1 tumor suppressor gene is heterozygously 
mutated. MEN1 is characterized by predisposition to pituitary, parathyroid, endocrine 
pancreas, and adrenocortical tumors (Lemos and Thakker 2008). The adrenocortical 
lesions are usually adenomas. Individuals with Beckwith-Wiedemann syndrome, 
linked to the 11p15 chromosomal locus which includes the growth regulatory gene 
P57kip2, IGF2 and H19, exhibit macrosomia, visceromegaly and various tumors, 
including adrenocortical tumors (Hatada and Mukai 2000; Hatada, et al. 1996; Ping, 
et al. 1989). 
 
The molecular bases of sporadic adrenocortical tumors are somewhat similar to the 
mutations in the above syndromes. Mutation in the TP53 gene is also implicated in 
sporadic adrenocortical cancer, and it is overall the most frequently mutated gene in 
human cancers (Hollstein, et al. 1991). Mutations in TP53 conserved exons 5–8 have 
been found in 20–27% of adrenocortical carcinomas and a small proportion of 
sporadic adrenocortical adenomas (Ohgaki, et al. 1993; Reincke, et al. 1994). 
Insulin-like growth factor (IGF) system mutations at the 11p15 locus, such as the 
P57kip2 mutation in Beckwith-Wiedemann syndrome, are documented in sporadic 
adrenocortical carcinoma (Soon, et al. 2008). Gsα has been reported as being 
occasionally mutated in sporadic adenomas, but not carcinomas (Fragoso, et al. 
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islet cell, anterior pituitary 
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ACA, 55%; 
ACC, rare 
Table 4. Syndromes that can be associated with adrenocortical neoplasia. Modified 
from (Soon et al. 2008). Abbreviations: MEN1, multiple endocrine neoplasia-1; PKA, 
protein kinase A; ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; 
PPNAD, primary pigmented nodular adrenocortical disease. 
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Aims of the Study 
 
This study was undertaken to elucidate the function and mechanisms of GATA 
factors in tumors of the adrenal cortex and in granulosa cells. 
 
The specific aims of the present study were: 
 
1. To investigate the cooperation of GATA-4 with TGF-β signaling in regulation of the 
inhibin-α gene in granulosa cells. 
 
2. To investigate the expression of GATA-4, GATA-6, LHR and steroidogenic 
markers in the gonadectomy-induced adrenocortical tumors of certain inbred strains 
of mice, and to assess the relative importance of the lack of gonadal hormones vs. 
the increase in gonadotropin levels in relation to the neoplastic phenomenon. 
 
3. To study the expression of components of the TGF-β and Wnt signaling cascades, 
compared with GATA-4/6, SF-1 and inhibin-α in human adrenocortical tumors. 
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Materials and Methods 
1 Patients and clinical data (I, IV) 
 
The Helsinki University Central Hospital Ethics Committee approved the use of 
human tissue samples and collection of clinical data from the patient registry, the 
Finnish Population Registry and Statistics Finland. The ovarian tissue samples were 
from women under 35 years of age operated upon because of cervical cancer, and 
the adrenocortical samples were from patients operated upon because of 
adrenocortical tumors. 
2 Experimental animals, serum samples and treatments (II, III) 
 
All animal work was carried out in the USA, in accordance with NIH Guidelines for 
the Care and Use of Laboratory Animals, and was approved by the institutional 
animal studies committee. 
 
Weanling FVB/N mice were obtained from the Department of Pediatrics, CHRC 
Genetically Altered Mouse Core. Weanling DBA/2J mice, C57BL/6J mice and mice 
homozygous for the Foxn1nu mutation in an NU/J background were purchased from 
The Jackson Laboratory (Bar Harbor, ME). At 3–4 wk of age, the mice were 
anesthetized and subjected to gonadectomy or sham surgery. Immediately after 
operations, nude NU/J mice were injected sc in each flank with 0.2 ml of hCG-CHO 
cells (see below) or control cell suspension. 
 
At specified times the mice were killed by CO2 inhalation, blood samples were 
collected and adrenals were harvested. Serum LH concentrations were measured 
using an immunofluorometric assay (Wallac Oy, Turku, Finland), as described 
previously (Haavisto, et al. 1993). Serum levels of hCG and testosterone were 
measured using commercial assay kits (Diagnostic Products Corp., Los Angeles, 
CA). Serum estradiol levels were determined by RIA (Spectria, Orion Diagnostica, 
Espoo, Finland). Corticosterone levels were also measured by RIA (IDS, Boldon, 
UK). 
3 Tissue samples 
3.1 Mouse (II, III) 
Harvested tissue was fixed overnight in 4% paraformaldehyde, embedded in paraffin, 
and sectioned for histochemical staining, immunohistochemistry or in situ 
hybridization. Alternatively, isolated adrenals were frozen in OCT compound (Tissue-
Tek, Torrance, CA) and sectioned. 
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3.2 Human (I, IV) 
Tissue samples were fixed overnight in formalin or Bouin’s fixative, embedded in 
paraffin, and sectioned for histochemical staining or immunohistochemistry. In some 
instances, small amounts of adrenocortical tumor tissue were additionally frozen for 
RNA analysis. 
4 Cell cultures and transient transfections (I, III) 
Cells were cultured at 37 °C in a humidified atmosphere containing 5% CO2. COS-7 
cells were cultured in DMEM supplemented with fetal bovine serum (FBS; 10%), 
penicillin (100 U/ml) and streptomycin (100 U/ml). KK-1 cells were originally 
established from an ovarian tumor of an Inha/Tag transgenic mouse and cultured in 
DMEM supplemented with glucose (4.5 g/l), L-glutamine (0.365 g/l), 20 mM Hepes, 
penicillin (100 U/ml) and streptomycin (100 U/ml). Chinese hamster ovary (CHO) 
cells stably expressing a biologically active single chain hCG variant (hCG-CHO 
cells) were prepared as described elsewhere (Ben-Menahem, et al. 2001; Sugahara, 
et al. 1995). hCG-CHO cells and control CHO cells were maintained in Ham’s F-12 
medium supplemented with fetal bovine serum (5%), G418 antibiotic solution (125 
µg/ml), penicillin (100 U/ml), streptomycin (100 µg/ml) and glutamine (2 mM). 
 
In cases of stimulation with TGF-β, the cells were treated with 0, 10, 20 or 50 ng 
TGF-β1/ml in FBS. COS-7 cells were transfected with FuGene6 (Roche) and KK-1 
cells with Lipofectamine 2000 (Invitrogen) according to the manufacturers’ 
instructions. The expression of all transfected plasmids was verified by Western 
blotting. In all experiments, pCMVβ-galactosidase (Clontech) was cotransfected to 
monitor transfection efficiency. When protein-expressing plasmids were transfected, 
an equal amount of corresponding empty plasmids was transfected to the other 
wells. Cells were lysed after transfection, and a luciferase assay normalized to β-
galactosidase activity was performed as previously described (Martelin, et al. 2000). 
 
The dominant negative GATA-4 mutant plasmid pMT2-GATA-4-DN2 (DN2) was 
generated by mutating the carboxy-terminal zinc-finger in the sequence coding for 
GATA-4 protein, using a Quick Change Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA, USA). The following primers were designed to change cysteines into 
serines in both positions of the zinc-finger: wild-type nucleotides 1437–1466, 
5’-GAGCCTGTATGTAATGCCTGCGGCCTCTAC-3’; mutant nucleotides 1437–1466, 
5’GAGCCTGTATCTAATGCCTCCGGCCTCTAC-3’. The changes were confirmed by 
sequencing, and the integrity of the mRNAs and proteins was confirmed by Northern 
and Western blotting respectively, as described by (Arceci, et al. 1993). The other 
plasmids employed have been previously described: pMT2-GATA-4 (wild-type 
GATA-4) and pMT2-GATA-4-DN1 (DN1) (Arceci et al. 1993), pGL2 –679 bp-inhibin-
α–luciferase (Tremblay and Viger 2001), Flag-pcDEF3-Smad2 and Flag-pcDEF3-
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Smad4 (Kawabata, et al. 1998), FlagpcDNA3-Smad3 (Nakao, et al. 1997), and 
pMT2-FOG-1 (Tsang et al. 1997) and pCS2+-FOG-2 (Tevosian, et al. 1999). In the 
wild-type and mutant –180 bp-inhibin-α–luciferase plasmids, we replaced the original 
pTKGH reporter vector (Ketola et al. 1999) with pGL2 by subcloning to the HindIII 
sites and sequencing to verify orientation. 
 
 
5 mRNA expression 
5.1 In situ hybridization (II, III) 
Frozen or paraffin-embedded tissue sections were subjected to in situ hybridization. 
The sections were deparaffinized, permeabilized, rehydrated, and then incubated in a 
final volume of 80 µl with 106 cpm 33P-labeled antisense riboprobe, prepared using 
[33P]UTP (3000 Ci/mmol; ICN Biomedicals) and the linearized plasmid templates 
described before: GATA-4 (Narita et al. 1997); GATA-6 (Narita et al. 1997); 11β-
hydroxylase (Domalik, et al. 1991); P450 aldosterone synthase (Domalik et al. 1991); 
inhibin-α (Esch, et al. 1987); StAR (Caron, et al. 1997); LHR (Kero, et al. 2000); SF-1 
(Sadovsky, et al. 1995); MC2R (Beuschlein et al. 2003); steroid 21-hydroxylase 
(Milstone, et al. 1992); and anti-Müllerian hormone (AMH) (Mishina, et al. 1996). 
Partial-length cDNAs for mouse P450scc and P450c17 were generated via RT-PCR 
of mRNA isolated from the Leydig cell tumor line mLTC-1 (Rebois 1982). Previously 
described primers (Arensburg, et al. 1999) were used to generate a PCR product 
spanning nucleotides 110–455 of mouse P450scc. A forward primer of 
5’-CCAGATGGTGACTCTAGGCCTCTTGTC and a reverse primer of 
5’-GGTCTATGGTAGTCAGTATGC were used to generate a PCR product spanning 
nucleotides 331–631of mouse P450c17 (Youngblood, et al. 1991). PCR reaction 
mixtures were processed for 30 cycles. The resultant PCR products were ligated into 
the T-A cloning site of pCRII (Invitrogen, Carlsbad, CA). 
 
5.2 Nuclear extracts and electrophoretic mobility shift assays (EMSAs) (I) 
To prepare nuclear extracts, cells were harvested in ice-cold PBS. After lysis in a 
buffer containing protease inhibitor cocktail P8340 (Sigma-Aldrich), 10 mM HEPES, 
1.5 mM MgCl2, 10 mM KCl and1 mM DTT, the cells were left on ice for 15 min and 
then vortexed for 10 s. After centrifugation for 5 s at 14 000 rpm, proteins from the 
nuclear pellet were extracted for 20 min on ice in a buffer containing protease 
inhibitor cocktail, 20 mM HEPES, 25% (vol./vol.) glycerol, 1.5 mM MgCl2, 0.2 mM 
EDTA, 420 mM NaCl and 1 mM DTT. Nuclear debris was removed by centrifugation 
for 5 min at 4°C at 14 000 rpm. Protein concentrations were measured using Bio-Rad 
DC protein assay (Bio-Rad Laboratories). Oligonucleotide probes for the desired 
area were end-labeled with γ-32P-ATP, using T4 polynucleotide kinase, and annealed 
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to dimers. In binding reactions, 10 µg of nuclear protein were incubated with 10 000–
30 000 c.p.m. of the labeled probe for 5 min on ice in 10 mM Hepes (pH 7.8), 1 mM 
EDTA, 5 mM MgCl2, 5% glycerol, 1 mM DTT and 1 µg poly-dIdC. The total reaction 
volume was 20 µl. The samples were loaded on a 5% acrylamide gel in 0.5x TBE, 
run at 200 V for 1.75–2 h at room temperature, and visualized by autoradiography. 
5.3 Reverse-transcriptase PCR (RT-PCR) (III, IV) 
Total RNA was isolated from frozen tissues by ultracentrifugation through a cesium 
chloride gradient; purified RNA (1 µg) was reverse-transcribed and 2 µl of the 
reaction mixture was used for each PCR reaction. Agarose gel electrophoresis (2%) 
demonstrated a band of expected size for each of the primer pairs. The following 
primers were used: β-catenin, 5′-GTTCGTGCACATCAGGATAC-3′ and 
5′-CGATAGCTAGGATCATCCTG -3′; LRP5, 5'-GCAAGAAGCTGTACTGGACG-3' 
and 5'-TGTTGCAGGCATGGATGGAG-3'; LRP6, 
5'-GATTATCCAGAAGGCATGGCAG-3' and 5'-TCCCATCACCATCTTCCA-3'; 
Smad2, 5′-GTTCCTGCCTTTGCTGAGAC-3’ and 5′-TCTCTTTGCCAGGAATGCTT-
3’; Smad3, 5′-TGCTGGTGACTGGATAGCAG-3’ and 
5′-CTCCTTGGAAGGTGCTGAAG-3’; aromatase, 
5’ ACAGCATTGTGATTGTCCCTCT-3’ and 5’-CATCTTGCGCTATTTGGCCTC-3’; 
hypoxanthine-guanine phosphoribosyl transferase (HPRT), 
5’-GCTGGTGAAAAGGACCTCT-3’ and 5’-CACAGGACTAGAACACCTGC-3’. 
5.4 RNase protection (II,III) 
The assays were performed with a commercially available kit (Ambion, Austin, TX) 
and 5 µg total RNA. 32P-labeled antisense riboprobes were prepared by in vitro 
transcription in the presence of [32P]CTP (800 Ci/mmol; ICN Biomedicals, Irvine, CA) 
using linearized plasmid templates and RNA polymerases. Protected fragments were 
separated by PAGE and quantified using phosphorimage analysis, normalizing to the 
expression of β-actin. Plasmid templates have been described previously: GATA-4 
(Narita et al. 1997); GATA-6 (Narita et al. 1997); and LHR (Kero et al. 2000). 
Preparation of the P450c17 template is described above (5.1). 
 
6 Protein expression 
6.1 Immunohistochemistry (I–IV) 
Paraffin-embedded tissue sections were deparaffinized and rehydrated. They were 
treated by boiling with citric acid (10 mM) and in some instances were also treated 
with H2O2 to quench endogenous peroxidase. After incubation with blocking buffer, 
the sections were incubated with primary antibodies (see table 5) for 1 h at 37 °C. 
Detection was performed using Vectastain ABC kits (Vector Laboratories, 
Burlingame, CA) and diaminobenzidine stain (Sigma-Aldrich Co., St. Louis, MO) 
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according to the manufacturers’ instructions. The sections were counterstained with 
hematoxylin. 
 
Staining results were evaluated by light microscopy. Human adrenocortical tumor 
samples were scored from 0 (benign) to 9 (highly malignant) according to the criteria 
of Weiss (Weiss 1984; Weiss et al. 1989) by an experienced pathologist (J.A.). 
Immunohistochemistry results were assessed by light microscopy and the 
percentage of positive tumor cells was scored from 0% to 100%, rounded to the 
nearest 10%. 
 
antibody company cat # dilution 
AMH Santa Cruz Biotechnology, Inc. sc-6886 1:200 
aromatase Santa Cruz Biotechnology, Inc. sc-14245 1:200 
β-catenin Zymed Laboratories 18-0226 1:500 
β-catenin Cell Signaling Technology, Inc. 9562 1:1000 
ERα Dako  1:500 
FOG-2 Santa Cruz Biotechnology, Inc. sc-9364 1:100 
GATA-4 Santa Cruz Biotechnology, Inc. sc-1237 1:200 
GATA-6 Santa Cruz Biotechnology, Inc. sc-9055 1:500, 1:50 
inhibin-α AbB Serotec MCA951S 1:20, 1:25 
LHR American Type Culture Collection CRL-2685  
LRP5 Abcam 38311 1:200 
LRP6 Cell Signaling Technology, Inc. 2560S  1:200 
PCNA Santa Cruz Biotechnology, Inc. sc-1797 1:800 
SF-1 Affinity Bioreagents, Inc. PAI-800 1:1000 
SF-1 Upstate Biotechnology 06-431 1:200 
Smad2 Zymed Laboratories 51-1300 1:100 
Smad3 Zymed Laboratories 51-1500 1:500 
Table 5. Antibodies utilized in immunohistochemistry, immunocytochemistry, protein 
co-immunoprecipitation and Western blotting. 
 
6.2 Immunocytochemistry (I) 
Cells were grown to form a monolayer and fixed with 4% paraformaldehyde. The 
staining procedure was the same as for the tissue sections. 
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6.3 Protein co-immunoprecipitation (I) 
Cells were transfected to express equal amounts of the proteins under study. 
Aliquots (100 µg) of cell nuclear extracts were immunoprecipitated by end-over-end 
mixing overnight at 4 °C with specific antibodies in PBS supplemented with NP40 
(1%), 1 mM EDTA and protease inhibitor cocktail. The protein complexes were 
collected by adding protein G-Sepharose for 1 h, followed by five washes with the 
buffer, and subjected to SDS–PAGE. Non-specific antibodies were employed in 
control experiments. 
6.4 Western blotting (I) 
Cell nuclear proteins or precipitated proteins were separated by means of 7.5% SDS-
PAGE and transferred to Immobilon-P membrane. Non-specific antibody binding was 
blocked with 5% skimmed milk in 0.1% Tween-TBS buffer. The membrane was 
incubated with the desired primary antibody for 1 h at room temperature, followed by 
secondary antibody, and visualized by using an Enhanced Chemiluminescence Plus 
Kit. For controls, the membranes were subsequently stripped and reprobed. 
 
7 Statistical analysis (I, III, IV) 
 
Cell culture results are presented as mean ± standard error of the mean of three 
independent experiments. The statistical significance of hormone measurement data 
was determined by using Student’s t test. In analysis of immunohistochemistry 
scoring results, differences between two groups were tested by using Wilcoxon’s 
(nonparametric) test, and correlations between continuous variables by using 
Spearman’s (nonparametric) rho. The analyses were performed using JMP 7.0 
software. A p value <0.05 was considered significant. 
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Results and Discussion 
 
1 Molecular interactions of GATA-4/6 (I) 
 
GATA-4 is an activator of many genes regulating endocrine function, including LHR, 
aromatase, anti-Müllerian hormone, inhibin-βB and inhibin-α (Feng, et al. 2000; 
Ketola et al. 1999; Rahman et al. 2004; Tremblay and Viger 1999, 2001). GATA-6 
has also been proposed to transactivate several of these regulators, albeit more 
weakly (Tremblay and Viger 2003a). Gonadotropins signal in endocrine cells through 
the cAMP-PKA pathway, which leads to phosphorylation of GATA-4, increasing its 
transactivation of target genes (Tremblay and Viger 2003a, b). Additionally, GATA 
factors are known to cooperate with TGF-β signaling in other organ systems (Blokzijl, 
et al. 2002; Brown, et al. 2004). 
 
We wanted to investigate the molecular interactions of GATA-4 in endocrine cell 
signaling. Our hypothesis was that GATA-4 cooperates with the TGF-β/Smad 
signaling cascade to regulate endocrine genes. We chose a cell line termed KK-1, 
derived from an ovarian tumor from a transgenic Inhα/Tag mouse (Kananen et al. 
1995). This cell line expresses factors present in normal ovarian granulosa cells, 
such as inhibin-α, GATA-4 and SF-1. We also utilized another cell line, COS-7 
epithelial cells, which does not express these endocrine factors but responds to a 
TGF-β/Smad3-type signal (Dennler, et al. 1998; Mazerbourg, et al. 2004). To study 
the effects on gene transcription, we utilized the inhibin-α promoter as an endocrine 
target. 
 
1.1 GATA-4/6 is required for inhibin-α promoter activation by TGF-β 
 
We found that in transient transfections TGF-β stimulation activated the inhibin-α 
promoter only in the presence of GATA-4. Exogenous TGF-β administered to the KK-
1 cells upregulated GATA-4 protein levels and increased the transcription of the 
inhibin-α promoter coupled to a luciferase reporter. In COS-7 cells, forced expression 
of GATA-4 was needed to activate the inhibin-α promoter (figure 8A), and a similar 
effect, although weaker, was observed with forced expression of GATA-6 (Parviainen 
et al., unpublished data). Overexpressing FOG-1 or FOG-2, in contrast, resulted in 
abolishment of the promoter activation in both cell lines (shown in COS-7 cells in 
figure 8A). As FOG proteins are known to be both coactivators and repressors of 
GATA factors (Svensson, et al. 2000a; Tsang, et al. 1997), the findings support our 
hypothesis that GATA proteins are activating factors in this setting. 
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In KK-1 cells, dominant negative (DN) GATA-4 variants or mutation of GATA-binding 
sites in the promoter could attenuate TGF-β responsiveness. These results are 
summarized in (figure 8B, C), and suggest that GATA-4 is required for TGF-β-
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Figure 8. Transient transfections of COS-7 and KK-1 cells. Luciferase activity, 
representing inhibin-α promoter activation, is presented as fold activation relative to control. 
A: COS-7 cells were transfected with the inhibin-α-luciferase construct, in the presence of 
GATA-4, FOG-1 and FOG-2 expression plasmids or the corresponding empty plasmids, and 
and with or without TGF-β. B: KK-1 cells were transfected with the inhibin-α-luciferase 
construct in the presence of dominant negative (DN) GATA-4 expression plasmids or the 
corresponding empty plasmids, and with or without TGF-β. DN1 lacked the N-terminal end of 
GATA-4 protein, and DN2 had the cysteines mutated on the C-terminal zinc-finger. C: KK-1 
cells were transiently transfected with either a wild-type or a mutant inhibin-α-luciferase 
construct, and with or without TGF-β. In mut1, the 5’ GATA site was mutated by replacing 
nucleotide G with C; in mut2, the 3’ GATA-site; and in mut1 and 2, both. D, E: COS-7 cells 
were transiently transfected with the inhibin-α-luciferase construct, in the presence of GATA-
4, Smad2 and Smad3 expression plasmids or the corresponding empty plasmids, and with or 
without TGF-β. 
1.2 Functional and physical interaction of GATA-4 and Smad3 
 
Smad proteins are the ubiquitous intracellular transmitters of the TGF-β signal (Shi 
and Massague 2003). Because the TGF-β-type signal is mediated via Smad2 and 
Smad3, we chose to investigate whether these two proteins cooperate with GATA-4. 
In transfections of COS-7 cells, GATA-4 synergism was specific to Smad3; with 
Smad2 administration, no enhanced transcription of inhibin-α was observed (figure 
8D, E). Functional GATA-4:Smad3 synergism was also evident in KK-1 cells. A 
Smad3 null mutation has been observed to downregulate inhibin-α expression in the 
ovary (Tomic, et al. 2004), which supports our finding that Smad2 and Smad3 
behave differently in this environment. 
 
We also introduced mutant GATA-4 constructs together with Smad3 in COS-7 cells 
and found that only administration of the DN construct that had the C-terminal zinc 
finger abolished resulted in failure to activate the inhibin-α promoter. Also in cardiac 
cells, GATA-4 and the TGF-β superfamily signal transmitters Smad1 and 4 cooperate 
to activate the Nkx2.5 promoter, and the interaction seems to require the C-terminal 
region of GATA-4 (Brown et al. 2004). Further, we were able to demonstrate (by 
means of immunoprecipitation experiments) endogenous physical Smad3:GATA-4 
interaction in KK-1 cells, and the same phenomenon was detected in transfected 
COS-7 cells (figure 9A, B). 
 
1.3 SF-1 cooperates with GATA-4 and Smad3 
 
Steroidogenic factor-1 (SF-1) is a GATA target gene (Tremblay and Viger 2001) and 
a key regulator of steroidogenic enzyme expression and the development of 
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mammalian adrenals, testes and ovaries (reviewed in Parker and Schimmer 1997). 
SF-1 has been shown to have significant synergism with GATA-4 in activating 
multiple gonadal gene promoters, including those of aromatase, anti-Müllerian 
hormone and inhibin-α (Tremblay and Viger 1999, 2001). We introduced SF-1 to the 
synergistic setting of GATA-4:Smad3, to improve the picture of these key players in 
the endocrine organs. In COS-7 cells, with no endogenous SF-1 expression, SF-1 
activated the inhibin-α promoter similarly to GATA-4, and acted synergistically with 
GATA-4 and with the GATA-4:Smad3 combination. In KK-1 cells, SF-1 similarly 
showed synergism with GATA-4 and Smad3, and the combination of the three 
players strongly enhanced TGF-β stimulation of the promoter, up to 11-fold (figure 





Figure 9.  A: COS-7 cells were transfected with GATA-4 and Smad3, and nuclear protein 
extracts were immunoprecipitated (IP) with anti-Smad3, following immunoblotting (IB) with 
GATA-4 and Smad3 antibodies. B: Nuclear protein extracts of KK-1 cells were 
immunoprecipitated with anti-Smad3, followed by immunoblotting with GATA-4 and Smad3 
antibodies. C: KK-1 cells were transiently transfected with the inhibin-α-luciferase construct, 
in the presence and absence of GATA-4, SF-1 and Smad3 expression plasmids and TGF-β. 
Luciferase fold activity is presented relative to the controls. 
 
Considering the other gonadal GATA targets, such as anti-Müllerian hormone 
(Tremblay and Viger 1999) and LHR (Rahman et al. 2004), these results altogether 
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suggest that GATA-4 is a link between endocrine and paracrine factors in endocrine 
cell gene regulation. The role of Smads in the transactivation of gonadal promoters 
has, however, only recently begun to evolve. By studying the GATA-4:Smad3 link 
further, we found that SF-1, both a target gene and an interacting partner for GATA 
factors in endocrine cells, is able to further enhance the GATA-4:Smad3 synergism. 
Thus, the regulation of inhibin-α expression may be orchestrated by a transcriptional 
module including GATA-4, Smad3 and SF-1. 
 
 
2 LH-dependent neoplasia of the mouse adrenal cortex (II, III) 
 
2.1 Gonadal characteristics in neoplastic cells 
 
We wanted to examine the expression profile of adrenocortical tumors in mice 
susceptible to gonadectomy-induced adrenocortical neoplasia. When 
gonadectomized, mice of the susceptible DBA/2J strain developed typical 
adrenocortical neoplasia consisting of A and B cells, as previously described (Fekete 
et al. 1941; Woolley et al. 1952). FVB/N mice, a non-susceptible strain, did not 
develop these changes. In the adrenals of DBA/2J mice, small A cells began to 
accumulate in the subcapsular region as early as a few weeks after gonadectomy. 
The A cells then migrated centripetally between the cell columns of the zF, and 
eventually disrupted the morphology of the zG and zF. By a few months after 
gonadectomy, large, lipid-laden B cells could be observed in between the A cells. 
 
The expression profiles of GATA-6 and GATA-4 in these tumors were of interest, 
since the former is abundantly expressed in normal adrenocortical cells and the latter 
is not normally detected postnatally. Immunohistochemical staining of the adrenals of 
gonadectomized DBA/2J mice, harvested 4 months after gonadectomy, showed that 
the normal GATA-6 nuclear expression was downregulated in the tumor area, 
whereas strong GATA-4 nuclear expression could be seen in tumor cells (figure 10). 








GATA-4 immunohistochemical staining of a 
neoplastic region in the adrenal cortex of a 
gonadectomized DBA/2J mouse. Both A and 
B cells have strong GATA-4 nuclear 
expression (brown stain), whereas the nuclei 
of adjacent normal adrenocortical cells 
remain negative (blue). Yellow arrows: A 
cells, red arrows: B cell. Modified from (II). 
 
We then further investigated the expression profile of the tumors, utilizing in situ 
hybridization to localize mRNA expression in the adrenal glands. As expected, A and 
B cells expressed GATA-4 mRNA. In addition, B cells expressed p450c17, a 
steroidogenic enzyme required for the synthesis of sex steroids, and normally 
expressed in the mouse adrenal cortex only during the fetal period. LH receptor 
(LHR) and inhibin-α were also expressed in B cells; inhibin-α also in A cells to a 
lesser extent. In contrast, A cells did not express p450c17 or LHR, and the 
expression pattern also significantly differed from that of normal adrenocortical cells, 
as A cells did not express SF-1, StAR or P450scc mRNA. This implies limited 
steroidogenic capacity in A cells, whereas B cells express the markers needed for 
sex steroid production, resembling the expression pattern in gonadal steroidogenic 
cells. 
 
To further characterize the contribution of gonadectomy and, on the other hand, 
gonadotropin elevation to the induction and progression of adrenocortical neoplasia, 
we created a mouse model employing female NU/J nude mice. The NU/J strain is an 
inbred strain carrying a loss-of-function mutation in the Foxn1 gene (Foxn1nu) that is 
associated with athymia (Balciunaite, et al. 2002). After gonadectomy, the NU/J mice 
developed adrenocortical neoplasia, morphologically comparable to the changes 
seen in DBA/2J mice.  Also similarly to the phenotype of gonadectomized DBA/2J 
mice, normal adrenocortical markers such as MC2R and 21-hydroxylase were absent 
from the neoplastic area, while ectopic expression of p450c17 and AMH receptor 
mRNA could be localized in B cells in in situ hybridization analysis. Ectopic 
immunohistochemical expression of GATA-4 in A and B cells was also similarly 
evident, as was the expression of LHR, inhibin-α and several other markers in B cells 
(figure 11). 
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Figure 11.  
Immunohistochemical expression 
of steroidogenic differentiation 
markers in the adrenal cortex of 
gonadectomized NU/J mice. 
GATA-4 expression is seen both 
in A and B cells (black arrows). 
SF-1 is expressed in normal 
adrenocortical cells and B cells, 
but is absent from A cells. LHR, 
AMH, inhibin-α, Smad3, 
aromatase and β-catenin 
















Taking advantage of the ability of NU/J mice to accept xenografts, we next assessed 
whether the adrenocortical tumorigenesis phenomenon is dependent directly on 
elevation of gonadotropin concentrations or on other changes induced by 
gonadectomy, e.g. lack of gonadal hormones. We utilized subcutaneous injections of 
cells secreting a single-chain variant of hCG known to bind to LH receptor (Sugahara 
et al. 1995). We found that non-gonadectomized mice with the hCG-secreting 
xenografts developed adrenocortical neoplasia morphologically very similar to the 
gonadectomized mice, and the expression patterns of GATA-4, inhibin-α and FOG-2 
were also similar. The expression of the sex steroidogenic markers LHR, P450c17 
and aromatase was, however, attenuated in the adrenals of hCG-treated mice 
compared with gonadectomized mice, as studied by RNase protection assays and 
RT-PCR. 
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Our results suggest that chronic elevation of gonadotropin concentrations is the 
principal signal responsible for adrenocortical tumorigenesis in susceptible strains of 
mice, but that it does not explain all the phenotypic changes, as the sex 
steroidogenic capacity of the hCG-treated mice was reduced. This might be a result 
of the effects of hCG on the ovaries, stimulating production of estrogen and 
testosterone. In addition, LH signaling could be decreased through down-regulation 
of LHR as a result of  elevated hCG levels (Ascoli, et al. 2002; Wang and Menon 
2005). 
 
2.2 GATA-4 and LHR in the adult adrenal cortex 
 
Early investigations on gonadectomized mice revealed that the developing 
adrenocortical neoplasia morphologically resembled gonadal stroma and was able to 
induce hormonal changes in mice normally achieved by ovarian steroid production 
(Fekete et al. 1941). Our studies suggest that the neoplastic cells not only are 
transformed to express gonad-specific genes, but also lose expression of 
characteristic adrenocortical genes. The ectopic expression of GATA-4, normally not 
expressed in the adult adrenal cortex, but abundantly in the gonads, has emerged as 
a hallmark of these tumors. In addition to the inbred mouse strains, the genetically 
modified models Inha/Tag and Inha-/- also exhibit GATA-4 expression in 
adrenocortical tumors (Looyenga and Hammer 2006; Rahman et al. 2004). Many of 
the other features of the inbred models are also similar (table 6). 
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 Normal cortex DBA NU/J nude Inhα/Tag Inh-/- 
GATA-4 - + + + + 
GATA-6 + - - - - 
LHR - + + + + 
Inhibin-α + + + + - 
AMH - n/a + n/a + 
P450c17 - + + n/a + 
aromatase - n/a + n/a + 
Table 6. Gene expression in adrenocortical neoplasms of gonadectomized DBA/2J, 
NU/J nude, Inhα/Tag and Inh-/- mice, and in normal adult mouse adrenal cortex. 
Modified from (Parviainen, et al. 2007). Abbreviations: LHR, luteinizing hormone 
receptor; AMH, anti-Müllerian hormone; P450c17, cytochrome P450 17α-
hydroxylase/17,20-lyase; n/a, unknown. 
 
 
Studying Inha-/- mice, two distinct cell types have been identified in the neoplastic 
area, one resembling theca cells and the other granulosa cells (Looyenga and 
Hammer 2006), corresponding to the A and B cells, respectively. Also similarly to our 
results, these neoplastic cells do not express typical adrenocortical genes such as 
Mc2r, Cyp11b1 or Cyp21. Type A cells, having a limited steroidogenic capacity, 
resemble postmenopausal ovarian stromal cells (Jabara, et al. 2003). The 
steroidogenic B cells resemble follicular theca cells found in patients with polycystic 
ovary syndrome (PCOS) (Kaaijk, et al. 2000), a condition characterized by elevated 
LH levels in the circulation. 
 
For LH to have a direct effect on cells, its receptor must be present. LHR is normally 
expressed in gonadal cells in adults, and very low levels of LHR have been detected 
in normal human adrenal cortex (Couzinet et al. 2001; Pabon et al. 1996). In fetal 
mice, however, considerable LHR expression has also been detected in the adrenal 
cortex; a developmental expression pattern resembling those of GATA-4 and 
P450c17 (Apaja, et al. 2005; Kiiveri et al. 2002; Rahman et al. 2004). The 
mechanism by which LHR expression is upregulated in neoplastic adrenocortical 
tissue is unknown, but it is conceivable that a subset of adrenocortical 
stem/progenitor cells expresses functional LHR and proliferates in response to the 
upregulated LH levels. Expression of GATA-4 is one of the earliest events in the 
neoplastic process and positive and reciprocal feed-forward amplification seems to 
exist between GATA-4 and LHR expression (Rahman et al. 2004). Furthermore, a 
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recent study has demonstrated that GATA-4 binds to LH β-subunit receptor and 
activates it in pituitary cells (Lo, et al. 2011). Whether a similar mechanism is active 
in the LH-dependent adrenocortical tumors is an interesting target for future 
investigation. 
 
Supporting the central role of GATA-4 in the expression of steroidogenic genes in the 
tumors, GATA-4 has been found to be sufficient to induce expression of 
steroidogenic markers in adrenocortical Y1 cells (Looyenga and Hammer 2006). We 
have examined the influence of exogenous GATA-4 protein in the adult mouse 
adrenal cortex of a non-susceptible strain (FVB/N) in the absence of LH stimulation 
(Parviainen et al., unpublished data). GATA-4 expression was driven in the mouse 
adrenal cortex by a p450c21 promoter (21OH/Gata4 mouse), which is expressed in 
differentiated mouse adrenocortical cells (Morley, et al. 1996). Preliminary results 
indicate that these mice develop subcapsular patches of GATA-4-positive cells in the 
adrenal cortex, resembling the A cells in the tumors of the inbred susceptible strains. 
GATA-6 expression is diminished and LHR expression upregulated in the neoplastic 
area (figure 12). Steroidogenic B cells do not seem to be present, in contrast to the 
other mouse models described above; this might be due to the introduction of GATA-
4 to the already differentiated adrenocortical cells. These results, however, highlight 




Expression of GATA-4 is 
upregulated and that of GATA-6 
and SF-1 downregulated in the 
spindle-shaped neoplastic cells 
of 21OH/Gata4 mice, compared 
to the adjacent normal 
adrenocortical cells. Ectopic 
LHR expression is seen in the 
neoplastic area. 
 
The hypothesis that mouse adrenocortical tumors arise from improperly specified 
adrenocortical stem/progenitor cells is supported by analogous human conditions. 
Several cases of thecal metaplasia of the adrenal have been reported in post-
menopausal women and in men with acquired testicular atrophy – both conditions 
characterized by chronically elevated levels of gonadotropins (Fidler 1977; 
Romberger and Wong 1989). The rare ACTH-independent Cushing syndrome in 
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pregnant women is also interesting as regards LH; in this condition, the adrenals 
respond to LH/hCG stimulation (Kasperlik-Zaluska, et al. 2000; Wy, et al. 2002). 
 
2.3 Mechanisms of subcapsular stem/progenitor cells 
 
The stem/progenitor cell theory in LH-dependent adrenocortical tumorigenesis is 
summarized in figure 13: in response to LH (instead of ACTH), the SF-1-positive 
subcapsular progenitors downregulate Dax1 and upregulate GATA-4, subsequently 





In response to elevated LH levels, the multipotential adrenocortical subcapsular progenitor 
cell differentiates into a gonadal-like cell. Modified from (Bielinska et al. 2009). 
 
 
It is interesting to note that SF-1, β-catenin and Smad3 are all expressed in the type 
B cells of NU/J mice. SF-1 has been shown to synergize with β-catenin in inducing 
the inhibin-α promoter in adrenocortical cells (Gummow et al. 2003), while GATA-4 
can also activate the SF-1 promoter and cooperate with SF-1 at the protein level 
(Tremblay and Viger 2003a). Upregulation of Smad3 together with GATA-4 has also 
been observed in Inh-/- adrenocortical tumors (Looyenga, et al. 2004), and we have 
shown in ovarian granulosa cells that GATA-4:Smad3 interaction is a mediator of 
TGF-ß signaling in the regulation of inhibin-α (I). All in all, the coexpression of GATA-
4, SF-1, β-catenin and Smad3 in gonadectomy-induced adrenocortical tumors would 
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suggest potential involvement of TGF-β and Wnt signaling cascades in the 
mechanisms of phenotypic switching from adrenocortical to gonadal-type cells. 
 
3 Human adrenocortical tumors and regulatory pathways (I–IV) 
 
The mouse models of adrenocortical tumorigenesis are indeed models, and it is of 
interest to investigate whether similar factors and mechanisms are present in human 
adrenocortical tumors. As mouse and human adrenal glands are functionally 
different, it could be presumed that the factors implicated in human adrenocortical 
tumor growth are not completely similar either. For instance, the human tumors do 
not generally depend on elevated levels of circulating gonadotropins – with the 
exceptions of thecal metaplasia in post-menopausal women (Fidler 1977) and in men 
with acquired testicular atrophy (Romberger and Wong 1989), and the ACTH-
independent Cushing syndrome in pregnant women, in which the adrenals respond 
to LH/hCG stimulation (Kasperlik-Zaluska et al. 2000; Wy et al. 2002). The mouse 
models have, however, provided information that can be utilized in the search for the 
mechanisms responsible for the growth of human tumors. 
3.1 Human adrenocortical tumors 
 
Next, we wanted to study whether the transcription factors and other regulators 
implicated in mouse studies are expressed in human adrenocortical tumors, and 
investigate the possible correlations of these factors in benign vs. malignant 
phenotype or other features of the tumors. We utilized a series of 31 human 
adrenocortical tumors, of which 13 were carcinomas. 
 
Inhibin-α seems to be a tumor suppressor in the mouse, as Inha-/- mice develop 
gonadal tumors and, when gonadectomized, adrenocortical tumors (Kananen et al. 
1996; Kananen et al. 1995). In human adrenocortical tumors, in contrast, no 
significant difference in inhibin-α expression between benign and malignant tumors 
has been found (Arola et al. 2000). Inhibin-α is nonetheless an interesting target for 
further research in adrenocortical tumors, as it is regulated by many of the factors 
expressed in the mouse tumor models, such as GATA-4 and 6, SF-1, β-catenin and 
Smad3 (I–III and Gummow et al. 2003; Looyenga et al. 2004; Tremblay and Viger 
2003a). β-catenin is the canonical intracellular mediator of the Wnt pathway, which is 
aberrantly active in various neoplastic processes, including human adrenocortical 
tumors (Tissier, et al. 2005; Willert and Jones 2006). The TGF-β pathway, in which 
Smad3 is a mediator, is also implicated in many malignant processes, either as a 
promoter or as an attenuator of tumor growth (Massague, et al. 2000).  
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We chose to study expression of the TGF-β pathway components Smad3 and 
Smad2 and the Wnt pathway components β-catenin and the co-receptors LRP5 and 
LRP6, in correlation with inhibin-α, GATA-6 and SF-1 expression. Our previous 
results with the same tumor series indicated that GATA-6 and SF-1 are 
predominantly expressed in benign tumors (Kiiveri et al. 2005), and we now wanted 
to further dissect the role of these transcription factors in the tumors. 
 
The Wnt pathway co-receptors LRP5 and LRP6 were predominantly expressed in 
benign tumors, although some expression was also detected in carcinomas. We 
divided the tumors by their Weiss scores into two groups, Weiss scores 0–3 and 4–9, 
and the expression of both receptors was significantly higher in the Weiss score 0–3 
group. In contrast, in β-catenin staining, no difference could be detected between the 
groups. This finding differs from previous results in a French tumor series, in which β-
catenin expression was higher in carcinomas (Gaujoux, et al.; Tissier et al. 2005). 
 
The expression profiles of Smad2 and Smad3 were clearly different, as Smad3 
expression was highest in tumors with a low Weiss score and Smad2 expression, in 
contrast, highest in the most malignant tumors. In addition, Smad3 expression 
correlated with that of inhibin-α, whereas expression of Smad2 did not, which is 
interesting considering our previous results concerning GATA-4/6 interaction in 
inhibin-α activation, which is specific to Smad3 (I). Of note, inhibin-α expression in 
our material also correlated with the Wnt pathway components LRP5, LRP6 and β-
catenin, and with SF-1. In the future, it would be interesting to investigate further 
whether or not the in vitro cooperation of SF-1 and β-catenin on inhibin-α activation 
(Gummow et al. 2003) is also present in human adrenocortical tumors. The 
expression of GATA-6 also correlated with that of inhibin-α, possibly relating to the 
ability of GATA-6 to transactivate the inhibin-α promoter (Tremblay and Viger 2001). 
 
Finally, both GATA-6 and SF-1 expression in carcinomas, although generally lower 
than in adenomas (Kiiveri et al. 2005), was also significantly more downregulated in 
those carcinomas that proved to be lethal. The results obtained concerning 
adrenocortical carcinomas are presented in figure 14. Considering the proposed 
tumor suppressor role of inhibin-α in the adrenal cortex (Looyenga et al. 2004), it 
could be hypothesized that in the most aggressive carcinomas, with poor outcome, 
inhibin-α transcription is attenuated as the intracellular and nuclear mediators 








Expression of the TGF-β 
signaling mediators Smad2 and 
Smad3 in adrenocortical 
carcinoma differed in that 
Smad2 expression was 
upregulated and Smad3 
downregulated as compared to 
adenomas. Expression of both 
LRP5 and LRP6 was reduced in 
carcinomas. SF-1 and GATA-6 
expression was downregulated 
in the most aggressive 
carcinomas. Abbreviations: 
DOD, died of disease; NDOD, 
not dead of disease. 
 
Aberrant GATA-4 expression has been detected in a subset of human adrenocortical 
tumors (Bassett et al. 2005; Kiiveri et al. 2005; Kiiveri et al. 1999), and high GATA-4 
expression has been associated with aggressive behavior (Barbosa et al. 2004). In 
our tumor material, GATA-4 mRNA expression could be detected in a subset of the 
tumors by RT-PCR, but no significant correlation was detected with the TGF-β 
cascade components or other factors studied (Kiiveri et al., unpublished data). We 
also assessed LHR mRNA expression in the tumors, which was evident in 
approximately half of the adenomas and in a minority of the carcinomas for which 
frozen tissue was available, but it also did not correlate with the other factors studied. 
These findings contrast with those in mouse models of adrenocortical tumorigenesis, 
in which GATA-4 and LHR expression are hallmarks of neoplastic growth (Bielinska 
et al. 2006). Although there obviously are differences between human adrenocortical 
tumors and the mouse models studied, some phenomena (such as diminished 
expression of GATA-6) are present in both. 
 
Adding to the tumor studies, we also studied the expression of the same factors in 
Wnt4 knockout mice (Parviainen et al., unpublished data). Wnt4 null mice have an 
adrenal phenotype of decreased expression of P450aldo and ectopic expression of 
P450c21 in the gonads, which suggests a role for Wnt4 in cell migration from the 
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urogenital ridge (Heikkila et al. 2002). We studied (by way of immunohistochemistry) 
the expression of Wnt pathway components and factors implicated in mouse and 
human adrenocortical tumorigenesis in Wnt4-/- mice. Since the mice do not survive 
postnatally as a result of kidney failure (Vainio et al. 1999), only fetal samples could 
be studied. Smad3 expression was slightly upregulated in the adrenals of knockout 
mice, while the expression levels of Smad2 and other factors such as inhibin-α, β-
catenin, LRP5/6 and GATA-4 were not significantly altered. These preliminary data 
suggest that the TGF-β/Smad3 pathway is upregulated in the adrenal cortex when 
Wnt signaling is absent, but additional studies are needed. 
3.2 Signaling cascades in adrenocortical tumors 
 
Presumably, there are several signaling cascades concomitantly active in both 
normal steroid-producing cells and adrenocortical tumor cells in humans and mice. 
We have studied the function of GATA factors that can affect gene expression in the 
cells both by direct transcriptional activation and by interacting with other regulators 
present. Our results suggest interactions of GATA-4 and GATA-6 with the TGF-β and 
Wnt signaling pathways. 
 
The putative intracellular cascades involving the GATA factors are summarized in 
figure 15. Signals are transmitted through cell surface receptors for TGF-β (RI and 
RII complex) and Wnt (complex of frizzled receptor and LRP co-receptor), and the G-
protein-coupled receptors for ACTH (MC2R) or LH (LHR), depending on the cell type. 
GATA-4 cooperates with Smad3 to upregulate inhibin-α transcription in the nucleus, 
and GATA-6 is also likely to be able to participate in the transcriptional module. SF-1 
and β-catenin cooperate to induce the same promoter (Gummow et al. 2003), while 
GATA-4 and GATA-6 are able to upregulate SF-1 transcription (Tremblay and Viger 
2001), and GATA-4 has been shown to interact directly with SF-1 in endocrine 
promoter transactivation (Tremblay and Viger 1999). The ACTH or LH signal is 
transmitted through the cAMP-PKA pathway, which, among its other effects, induces 
GATA-4 and GATA-6 expression (Tremblay and Viger 2003a, b), increasing the 
transactivation of, for example, inhibin-α. Other as yet unidentified factors are likely to 
be present in the promoter transactivation complex. 






A hypothetical model of the participation of GATA-4 and GATA-6 in gene transcription in 
steroid-producing cells. See text for details. 
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Conclusions and Future Perspectives 
 
1. GATA-4 and Smad3 physically cooperate to induce inhibin-α in granulosa cells 
and are likely to participate in a transcriptional module orchestrating inhibin-α 
activation in endocrine tissues. 
 
2. GATA-4 expression is dramatically upregulated and GATA-6 downregulated in 
gonadectomy-induced adrenocortical tumors of inbred mice. Ectopic expression of 
GATA-4 and LHR in these tumors is associated with changes in cell proliferation, 
differentiation and steroid production. 
 
3. Chronic elevation of circulating gonadotropin concentrations, caused by either 
gonadectomy or hCG administration, induces the neoplastic process in the adrenal 
cortex of susceptible inbred mice. A population of cells in the subcapsular region 
undergoes differentiation along a gonadal rather than an adrenal route, leading to 
sex steroid production by the tumors. 
 
4. The signaling cascade components and transcription factors driving inhibin-α 
expression are reduced in ACC with poor outcome, suggesting a role for inhibin-α as 
a tumor suppressor. The results suggest pathways associated with adrenocortical 
tumor aggressiveness. 
 
Research on adrenocortical tumors has in recent years led to the identification of 
dysregulated gene mutations and signaling pathways, by means of gene expression 
profiling of tumor samples and analysis of human genetic disorders that predispose 
individuals to adrenocortical tumors. However, the molecular events behind the 
frequent benign tumors and the rare event of malignant transformation in the adrenal 
cortex remain unknown. The availability of inbred and genetically engineered mouse 
models has enabled research on adrenocortical stem/progenitor cells that may 
elucidate the genetic and epigenetic events behind both tumor types. Specifically, it 
would be of interest to further dissect the role of GATA-4 in adrenocortical tumors by 
introducing ectopic GATA-4 expression in mouse subcapsular progenitor cells. 
Another approach is investigation of the adrenal phenotype in intact and 






Based on current knowledge it can be assumed that GATA factors and their 
cofactors are important regulators of the development and function of the adrenal 
gland, and that abnormalities in their expression or in the genes coding for them may 
lead to disease and tumors in the adrenal cortex. Abnormalities in transcription have 
been linked to developmental diseases and tumorigenesis in many organ systems, 
but such events have until recently been poorly understood in the adrenal cortex. 
 
Analyses of heritable and spontaneous types of human adrenocortical tumors have 
revealed alterations in either cell surface receptors or their downstream effectors, 
and mouse models have enabled research on the mechanisms behind neoplastic 
transformation and tumor growth. Better understanding of the basic molecular 
mechanisms controlling organ development and leading to tumor formation is needed 
to ultimately improve diagnostics and to develop new treatment strategies for benign 
and malignant adrenocortical tumors. 
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